These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36977286)

  • 1. Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy.
    Squifflet P; Saad ED; Loibl S; van Mackelenbergh MT; Untch M; Rastogi P; Gianni L; Schneeweiss A; Conte P; Piccart M; Bonnefoi H; Jackisch C; Nekljudova V; Tang G; Valagussa P; Neate C; Gelber R; Poncet C; Heinzmann D; Denkert C; Geyer CE; Cortes J; Guarneri V; de Azambuja E; Cameron D; Ismael G; Wolmark N; Cortazar P; Buyse M;
    J Clin Oncol; 2023 Jun; 41(16):2988-2997. PubMed ID: 36977286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
    van Mackelenbergh MT; Loibl S; Untch M; Buyse M; Geyer CE; Gianni L; Schneeweiss A; Conte P; Piccart M; Bonnefoi H; Jackisch C; Nekljudova V; Tang G; Valagussa P; Neate C; Gelber R; Poncet C; Squifflet P; Saad ED; Heinzmann D; Denkert C; Rastogi P; Cortes J; Guarneri V; de Azambuja E; Cameron D; Ismael G; Wolmark N; Cortazar P;
    J Clin Oncol; 2023 Jun; 41(16):2998-3008. PubMed ID: 37075276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.
    Huober J; Holmes E; Baselga J; de Azambuja E; Untch M; Fumagalli D; Sarp S; Lang I; Smith I; Boyle F; Xu B; Lecocq C; Wildiers H; Jouannaud C; Hackman J; Dasappa L; Ciruelos E; Toral Pena JC; Adamchuk H; Hickish T; de la Pena L; Jackisch C; Gelber RD; Piccart-Gebhart M; Di Cosimo S
    Eur J Cancer; 2019 Sep; 118():169-177. PubMed ID: 31377477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
    Cortazar P; Zhang L; Untch M; Mehta K; Costantino JP; Wolmark N; Bonnefoi H; Cameron D; Gianni L; Valagussa P; Swain SM; Prowell T; Loibl S; Wickerham DL; Bogaerts J; Baselga J; Perou C; Blumenthal G; Blohmer J; Mamounas EP; Bergh J; Semiglazov V; Justice R; Eidtmann H; Paik S; Piccart M; Sridhara R; Fasching PA; Slaets L; Tang S; Gerber B; Geyer CE; Pazdur R; Ditsch N; Rastogi P; Eiermann W; von Minckwitz G
    Lancet; 2014 Jul; 384(9938):164-72. PubMed ID: 24529560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
    JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.
    Broglio KR; Quintana M; Foster M; Olinger M; McGlothlin A; Berry SM; Boileau JF; Brezden-Masley C; Chia S; Dent S; Gelmon K; Paterson A; Rayson D; Berry DA
    JAMA Oncol; 2016 Jun; 2(6):751-60. PubMed ID: 26914222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer.
    Chen HL; Chen Q; Deng YC
    Medicine (Baltimore); 2021 Nov; 100(44):e27632. PubMed ID: 34871229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
    ; Yee D; DeMichele AM; Yau C; Isaacs C; Symmans WF; Albain KS; Chen YY; Krings G; Wei S; Harada S; Datnow B; Fadare O; Klein M; Pambuccian S; Chen B; Adamson K; Sams S; Mhawech-Fauceglia P; Magliocco A; Feldman M; Rendi M; Sattar H; Zeck J; Ocal IT; Tawfik O; LeBeau LG; Sahoo S; Vinh T; Chien AJ; Forero-Torres A; Stringer-Reasor E; Wallace AM; Pusztai L; Boughey JC; Ellis ED; Elias AD; Lu J; Lang JE; Han HS; Clark AS; Nanda R; Northfelt DW; Khan QJ; Viscusi RK; Euhus DM; Edmiston KK; Chui SY; Kemmer K; Park JW; Liu MC; Olopade O; Leyland-Jones B; Tripathy D; Moulder SL; Rugo HS; Schwab R; Lo S; Helsten T; Beckwith H; Haugen P; Hylton NM; Van't Veer LJ; Perlmutter J; Melisko ME; Wilson A; Peterson G; Asare AL; Buxton MB; Paoloni M; Clennell JL; Hirst GL; Singhrao R; Steeg K; Matthews JB; Asare SM; Sanil A; Berry SM; Esserman LJ; Berry DA
    JAMA Oncol; 2020 Sep; 6(9):1355-1362. PubMed ID: 32701140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.
    Attard CL; Pepper AN; Brown ST; Thompson MF; Thuresson PO; Yunger S; Dent S; Paterson AH; Wells GA
    J Med Econ; 2015 Mar; 18(3):173-88. PubMed ID: 25347449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
    Untch M; von Minckwitz G; Gerber B; Schem C; Rezai M; Fasching PA; Tesch H; Eggemann H; Hanusch C; Huober J; Solbach C; Jackisch C; Kunz G; Blohmer JU; Hauschild M; Fehm T; Nekljudova V; Loibl S;
    J Clin Oncol; 2018 May; 36(13):1308-1316. PubMed ID: 29543566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
    Michiels S; Pugliano L; Marguet S; Grun D; Barinoff J; Cameron D; Cobleigh M; Di Leo A; Johnston S; Gasparini G; Kaufman B; Marty M; Nekljudova V; Paluch-Shimon S; Penault-Llorca F; Slamon D; Vogel C; von Minckwitz G; Buyse M; Piccart M
    Ann Oncol; 2016 Jun; 27(6):1029-1034. PubMed ID: 26961151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
    Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C
    Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
    Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
    Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer.
    Korn EL; Sachs MC; McShane LM
    Ann Oncol; 2016 Jan; 27(1):10-5. PubMed ID: 26489443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.
    Jackisch C; Hegg R; Stroyakovskiy D; Ahn JS; Melichar B; Chen SC; Kim SB; Lichinitser M; Starosławska E; Kunz G; Falcon S; Chen ST; Crepelle-Fléchais A; Heinzmann D; Shing M; Pivot X
    Eur J Cancer; 2016 Jul; 62():62-75. PubMed ID: 27208905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer.
    Choi JH; Jeon CW; Kim YO; Jung S
    Medicine (Baltimore); 2020 Nov; 99(46):e23053. PubMed ID: 33181670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
    Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
    J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer.
    Tanaka S; Iwamoto M; Kimura K; Matsunami N; Morishima H; Yoshidome K; Nomura T; Morimoto T; Yamamoto D; Tsubota Y; Kobayashi T; Uchiyama K
    Clin Breast Cancer; 2015 Jun; 15(3):191-6. PubMed ID: 25579459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.
    Singer CF; Tan YY; Fitzal F; Steger GG; Egle D; Reiner A; Rudas M; Moinfar F; Gruber C; Petru E; Bartsch R; Tendl KA; Fuchs D; Seifert M; Exner R; Balic M; Bago-Horvath Z; Filipits M; Gnant M;
    Clin Cancer Res; 2017 Jul; 23(14):3676-3683. PubMed ID: 28143867
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.